RG
CBIO

Redmile Group’s Crescent Biopharma CBIO Stock Holding History

Redmile Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,535
Closed -$578K – 83
2020
Q1 		$578K Sell
2,535
-10,903
-81% -$4.17M 0.02% 65
2019
Q4 		$7.11M Sell
13,438
-6,538
-33% -$3.54M 0.17% 57
2019
Q3 		$8.61M Sell
19,976
-108
-0.5% -$69.5K 0.29% 55
2019
Q2 		$23.9M Sell
20,084
-98
-0.5% -$117K 0.68% 45
2019
Q1 		$25.1M Buy
20,182
+397
+2% +$455K 0.74% 41
2018
Q4 		$18.7M Sell
19,785
-696
-3% -$838K 0.75% 42
2018
Q3 		$29.5M Buy
20,481
+188
+0.9% +$284K 0.91% 41
2018
Q2 		$32.7M Sell
20,293
-2,530
-11% -$4.35M 1.11% 32
2018
Q1 		$37M Buy
22,823
+3,516
+18% +$7.31M 1.43% 27
2017
Q4 		$32.4M Buy
19,307
+7,166
+59% +$9.48M 1.41% 25
2017
Q3 		$17M Buy
12,141
+6,145
+102% +$7.21M 0.84% 36
2017
Q2 		$6.69M Buy
+5,996
New +$4.95M 0.41% 49

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group's CBIO Position: Q2 2020 in Review

Redmile Group sold out of Crescent Biopharma (CBIO) in Q2 2020, closing a stake of 2,535 shares — an estimated $578K sold.

Redmile Group first reported a position in CBIO in Q2 2017 and held it in 12 quarters. The position peaked at $37M in Q1 2018. 87 funds tracked by Wall St. Rank hold CBIO as of Q2 2020.

  • Redmile Group reported no remaining Crescent Biopharma position as of Q2 2020 after selling out during the quarter.
  • Redmile Group sold 2,535 Crescent Biopharma shares in Q2 2020, an estimated $578K.
  • Redmile Group first reported a position in Crescent Biopharma in Q2 2017 and held it in 12 quarters.
  • Redmile Group's Crescent Biopharma position peaked at $37M in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2020.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.